The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Open accessAbstract
BACKGROUND: mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“HRD targeted therapy with PARPi is mostly restricted to breast and ovarian cancer5, though its use for treating pancreatic cancer was recently approved by the FDA (US Food and Drug Administration)29.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [29]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Finally, in late-stage PDAC with germline mutation in BRCA1 or BRCA2 (~7.5% of the patients), the PARP inhibitor olaparib could extend progression free survival but not overall survival (8).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [8]
In the citing paper
“a pivotal clinical trial in patients with PDAC and germline BRCA1/2 mutations established the benefit of administering an orally bioavailable PARP inhibitor on improved progression free survival (PFS). This led to the approval of targeted therapy in this setting87.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationEpidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Cited by
Sorted by citations
Items 201–300 of 1,002
Li, G., Lin, S., Yu, Z., Wu, X.-H., Liu, J., Tu, G., Liu, Q., Tang, Y.-L., Jiang, Q., Xu, J.-H., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115329 · Cited by 77
Mainstream consent programs for genetic counseling in cancer patients: A systematic review
Scheinberg, T., Young, A. L., Woo, H. H., Goodwin, A., Mahon, K. L., & Horvath, L. G. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13334 · Cited by 72
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
Heredia-Soto, V., Rodrı́guez-Salas, N., & Feliú, J. (2021) · Cancers · doi:10.3390/cancers13081986 · Cited by 74
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Khamidullina, A. I., Abramenko, Y. E., Bruter, A. V., & Tatarskiy, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021263 · Cited by 73
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
Casolino, R., Braconi, C., Malleo, G., Paiella, S., Bassi, C., Milella, M., Dreyer, S. B., Froeling, F. E. M., Chang, D. K.-F., Biankin, A. V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.013 · Cited by 68
Self-citationPARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
Sim, H., Galanis, E., & Khasraw, M. (2022) · Cancers · doi:10.3390/cancers14041003 · Cited by 70
Booth, C. M., Eisenhauer, E. A., Gyawali, B., & Tannock, I. F. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01423 · Cited by 75
Recent advances in the treatment of pancreatic cancer
Roth, M. T., Cardin, D. B., & Berlin, J. D. (2020) · F1000Research · doi:10.12688/f1000research.21981.1 · Cited by 68
Wang, C., & Li, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13349 · Cited by 66
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation
Nelson, R., Seligson, N. D., Bottiglieri, S., Carballido, E. M., Cueto, A. D., Imanirad, I., Levine, R. M., Parker, A. S., Swain, S. M., Tillman, E. M., et al. (2021) · Cancers · doi:10.3390/cancers13071566 · Cited by 69
BRCA-mutant pancreatic ductal adenocarcinoma
Lai, E., Ziranu, P., Spanu, D., Dubois, M., Pretta, A., Tolu, S., Camera, S., Liscia, N., Mariani, S., Persano, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01469-9 · Cited by 71
Terrero, G., Datta, J., Dennison, J. L., Sussman, D. A., Lohse, I., Merchant, N. B., & Hosein, P. J. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0611 · Cited by 67
Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
Samuel, J. N., Booth, C. M., Eisenhauer, E. A., Brundage, M., Berry, S. R., & Gyawali, B. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0864 · Cited by 67
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 71
Taı̈eb, J., Prager, G. W., Melisi, D., Westphalen, C. B., D’Esquermes, N., Ferreras, A., Carrato, A., & Macarulla, T. M. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000587 · Cited by 66
Self-citationBeutel, A. K., Schütte, L. D., Scheible, J., Roger, É., Müller, M., Perkhofer, L., Kestler, A. M. T. U., Kraus, J. M., Kestler, H. A., Barth, T. F. E., et al. (2021) · Cancers · doi:10.3390/cancers13112539 · Cited by 67
Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 67
PARP mediated DNA damage response, genomic stability and immune responses
Zong, C., Zhu, T., He, J., Huang, R., Jia, R., & Shen, J. (2021) · International Journal of Cancer · doi:10.1002/ijc.33918 · Cited by 70
Russo, A. D., Incorvaia, L., Capoluongo, E., Tagliaferri, P., Gori, S., Cortesi, L., Genuardi, M., Turchetti, D., Giorgi, U. D., Maïo, M. D., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100459 · Cited by 65
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
Varghese, A. M., Singh, I., Singh, R., Kunte, S., Chou, J. F., Capanu, M., Wong, W., Lowery, M. A., Stadler, Z. K., Salo‐Mullen, E. E., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab038 · Cited by 68
Self-citationThe Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
Sturm, N., Ettrich, T. J., & Perkhofer, L. (2022) · Cancers · doi:10.3390/cancers14010217 · Cited by 68
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Concannon, K., Morris, B. B., Gay, C. M., & Byers, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.031 · Cited by 71
Oh, G., Wang, A., Wang, L., Li, J., Werba, G., Weissinger, D., Zhao, E., Dhara, S., Hernandez, R. E., Ackermann, A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165934 · Cited by 69
Self-citationVeneris, J. T., Matulonis, U. A., Liu, J. F., & Konstantinopoulos, P. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.09.021 · Cited by 62
Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice
Fassan, M., Scarpa, A., Remo, A., Maglio, G. D., Troncone, G., Marchetti, A., Doglioni, C., Ingravallo, G., Perrone, G., Parente, P., et al. (2020) · Pathologica · doi:10.32074/1591-951x-158 · Cited by 64
Clinical considerations for the management of androgen indifferent prostate cancer
Berchuck, J. E., Viscuse, P. V., Beltran, H., & Aparicio, A. M. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00332-5 · Cited by 63
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
Schettini, F., Giudici, F., Bernocchi, O., Sirico, M., Corona, S. P., Giuliano, M., Locci, M., Paris, I., Scambia, G., Placido, S. D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.035 · Cited by 65
Lamberti, G., Sisi, M., Andrini, E., Palladini, A., Giunchi, F., Lollini, P., Ardizzoni, A., & Gelsomino, F. (2020) · Cancers · doi:10.3390/cancers12113129 · Cited by 66
PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies
Mucileanu, A., Chira, R. I., & Mircea, P. A. (2021) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2116 · Cited by 60
Horgan, D., Curigliano, G., Rieß, O., Hofman, P. M., Büttner, R., Conte, P., Čufer, T., Gallagher, W. M., Georges, N., Kerr, K. M., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010072 · Cited by 68
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
Zhang, X., Mao, T., Zhang, B., Xu, H., Cui, J., Jiao, F., Chen, D., Wang, Y., Hu, J., Xia, Q., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103897 · Cited by 62
Curtin, N. J., Bànyai, K., Thaventhiran, J. E. D., Quesne, J. P. C. L., Helyes, Z., & Bai, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15137 · Cited by 61
Durinikova, E., Buzo, K., & Arena, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01981-z · Cited by 61
Peng, X., Pan, W., Jiang, F., Chen, W., Qi, Z., Peng, W., & Chen, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106529 · Cited by 65
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions
Sturm, N., Schuhbaur, J., Hüttner, F. J., Perkhofer, L., & Ettrich, T. J. (2022) · Cancers · doi:10.3390/cancers14225580 · Cited by 65
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
Pham, T. D., Shields, M. A., Spaulding, C., Principe, D. R., Li, B., Underwood, P. W., Trevino, J. G., Bentrem, D. J., & Munshi, H. G. (2021) · Cancers · doi:10.3390/cancers13030440 · Cited by 64
Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology
Rousset-Rouviere, S., Rochigneux, P., Chrétien, A.-S., Fattori, S., Gorvel, L., Provansal, M., Lambaudie, É., Olive, D., & Sabatier, R. (2021) · Biomedicines · doi:10.3390/biomedicines9060632 · Cited by 60
Informative censoring of surrogate end-point data in phase 3 oncology trials
Gilboa, S., Pras, Y., Mataraso, A., Bomze, D., Markel, G., & Meirson, T. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.044 · Cited by 58
Ghafoor, A., Mian, I., Wagner, C., Mallory, Y., Agra, M., Morrow, B., Wei, J. S., Khan, J. I., Thomas, A., Sengupta, M., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100231 · Cited by 62
Synthetic Lethality through the Lens of Medicinal Chemistry
Myers, S. H., Ortega, J. A., & Cavalli, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00766 · Cited by 63
Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
Federico, A. D., Tateo, V., Parisi, C., Formica, F., Carloni, R., Frega, G., Rizzo, A., Ricci, D., Marco, M. D., Palloni, A., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14070677 · Cited by 61
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
Terraf, P., Pareja, F. G., Brown, D. N., Ceyhan‐Birsoy, O., Misyura, M., Rana, S., O'Reilly, E. M., Carlo, M. I., Aghajanian, C. A., Liu, Y. L., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.006 · Cited by 61
Self-citationEverything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents
Martorana, F., da Silva, L. A., Sessa, C., & Colombo, I. (2022) · Cancers · doi:10.3390/cancers14040953 · Cited by 61
Overcoming therapy resistance in pancreatic cancer: New insights and future directions
Espona‐Fiedler, M., Patthey, C., Lindblad, S., Sarró, I., & Öhlund, D. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116492 · Cited by 62
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?
Katayama, E., Hue, J. J., Bajor, D. L., Ocuin, L. M., Ammori, J. B., Hardacre, J. M., & Winter, J. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27727 · Cited by 58
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Palacín-Aliana, I., Garcia‐Romero, N., Asensi-Puig, A., Carrión-Navarro, J., González‐Rumayor, V., & Ayuso‐Sacido, Á. (2021) · Biomedicines · doi:10.3390/biomedicines9080906 · Cited by 63
Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients
Gyawali, B., & Booth, C. M. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00516-8 · Cited by 62
BRCA1, BRCA2 , and Associated Cancer Risks and Management for Male Patients
Cheng, H. H., Shevach, J. W., Castro, E., Couch, F. J., Domchek, S. M., Eeles, R. A., Giri, V. N., Hall, M. J., King, M., Lin, D. W., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2185 · Cited by 63
Self-citationCurrent Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer
Regel, I., Mayerle, J. V., & Mukund, M. U. (2020) · Cancers · doi:10.3390/cancers12041024 · Cited by 61
Sarcopenia in aging, obesity, and cancer
Ligibel, J. A., Schmitz, K. H., & Berger, N. A. (2020) · Translational Cancer Research · doi:10.21037/tcr-2019-eaoc-05 · Cited by 60
Bagnolini, G., Milano, D., Manerba, M., Schipani, F., Ortega, J. A., Gioia, D., Falchi, F., Balboni, A., Farabegoli, F., Franco, F., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01526 · Cited by 57
Molecular Trajectory of BRCA1 and BRCA2 Mutations
Hatano, Y., Tamada, M., Matsuo, M., & Hara, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00361 · Cited by 58
Michl, P., Löhr, M. J., Neoptolemos, J. P., Capurso, G., Rebours, V., Malats, N., Ollivier, M., & Ricciardiello, L. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12123 · Cited by 60
Chiorean, E. G., Guthrie, K. A., Philip, P. A., Swisher, E. M., Jalikis, F. G., Pishvaian, M. J., Berlin, J. D., Noel, M. S., Suga, J. M., Garrido‐Laguna, I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1789 · Cited by 57
Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features
Thompson, E. D., & Wood, L. D. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0472-ra · Cited by 56
Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer
Driescher, C., Fuchs, K., Häberle, L., Goering, W., Frohn, L., Opitz, F. V., Haeussinger, D., Knoefel, W. T., Keitel, V., & Esposito, I. (2020) · Cancers · doi:10.3390/cancers13010039 · Cited by 57
Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics
Advani, D., Sharma, S., Kumari, S., Ambasta, R. K., & Kumar, P. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210308101029 · Cited by 63
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Leibowitz, B. D., Dougherty, B. V., Bell, J. S. K., Kapilivsky, J., Michuda, J., Sedgewick, A. J., Munson, W., Chandra, T. A., Dry, J. R., Beaubier, N. T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09669-z · Cited by 58
Pismataro, M. C., Astolfi, A., Barreca, M. L., Pacetti, M., Schenone, S., Bandiera, T., Carbone, A., & Massari, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02101 · Cited by 60
Mastrantoni, L., Chiaravalli, M., Spring, A., Beccia, V., Bello, A. D., Bagalá, C., Bensi, M., Barone, D., Trovato, G., Caira, G., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00511-4 · Cited by 61
Self-citationCracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
Paulet, L., Trécourt, A., Leary, A. F., Péron, J., Descôtes, F., Devouassoux‐Shisheboran, M., Leroy, K., You, B., & Lopez, J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.037 · Cited by 57
Wu, Y., Hung, Y., Chiu, N., Lee, R., Li, C., Chao, Y., Shyr, Y., Wang, S., Chen, S., Lin, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.030 · Cited by 56
PARP Inhibitors in Breast and Ovarian Cancer
Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L., & Heong, V. Y. M. (2023) · Cancers · doi:10.3390/cancers15082357 · Cited by 60
Precision medicine for metastatic colorectal cancer: an evolving era
Güler, İ., Aşkan, G., Klostergaard, J., & Şahin, İ. H. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1663174 · Cited by 56
Rainone, M., Singh, I., Salo‐Mullen, E. E., Stadler, Z. K., & O'Reilly, E. M. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5963 · Cited by 60
Self-citationHarnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
Maia, M. C., Salgia, M. M., & Pal, S. K. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0297-9 · Cited by 56
Bazzichetto, C., Luchini, C., Conciatori, F., Vaccaro, V., Cello, I. D., Mattiolo, P., Falcone, I., Ferretti, G., Scarpa, A., Cognetti, F., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228841 · Cited by 58
Herzog, T. J., Vergote, I. B., Gomella, L. G., Milenkova, T., French, T., Tonikian, R., Poehlein, C. H., & Hussain, M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.10.021 · Cited by 57
Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice
Hicks, J. K., Howard, R., Reisman, P., Adashek, J. J., Fields, K. K., Gray, J. E., McIver, B., McKee, K. J., O’Leary, M. F., Perkins, R. M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00513 · Cited by 54
Schneider, B. P., Jiang, G., Ballinger, T. J., Shen, F., Chitambar, C. R., Nanda, R., Falkson, C. I., Lynce, F. C., Gallagher, C., Isaacs, C. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01657 · Cited by 55
PARP Inhibitors in Pancreatic Cancer
Brown, T. J., & Reiss, K. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000554 · Cited by 55
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Sochacka-Ćwikła, A., Mą̨czyński, M., & Regiec, A. (2022) · Molecules · doi:10.3390/molecules27072259 · Cited by 56
Gupta, M., Sherrow, C., Krone, M. E., Blais, E. M., Pishvaian, M. J., Petricoin, E. F., Matrisian, L. M., DeArbeloa, P., Gregory, G., Brown, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7641 · Cited by 55
Reading ADP-ribosylation signaling using chemical biology and interaction proteomics
Kliza, K. W., Liu, Q., Roosenboom, L. W. M., Jansen, P. W. T. C., Filippov, D. V., & Vermeulen, M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.037 · Cited by 52
Alewine, C., Ahmad, M. I., Peer, C. J., Hu, Z. I., Lee, M.-J., Yuno, A., Kindrick, J. D., Thomas, A., Steinberg, S. M., Trepel, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2586 · Cited by 52
Hu, X., Zhang, J., Zhang, Y., Jiao, F., Wang, J., Chen, H., Ouyang, L., & Wang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114094 · Cited by 51
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Lo, J. H.-J., Agarwal, R., Goff, L. W., & Heumann, T. R. (2023) · Cancers · doi:10.3390/cancers15133312 · Cited by 52
Meng, Z., Rodriguez-Ehrenfried, A., Tan, C. L., Steffens, L. K., Kehm, H., Zens, S., Lauenstein, C., Paul, A., Schwab, M., Förster, J. D., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh9562 · Cited by 53
Ikezawa, K., Urabe, M., Kai, Y., Takada, R., Akita, H., Nagata, S., & Ohkawa, K. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad176 · Cited by 52
Zhu, Q., Dai, Q., Zhao, L., Zheng, C., Li, Q., Yuan, Z., Li, L., Xie, Z., Qiu, Z., Huang, W., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06303-z · Cited by 55
Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review
Hayat, U., Croce, P., Saadeh, A., Desai, K., Appiah, J., Khan, S., Khan, Y. I., Kumar, K., & Hanif, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041129 · Cited by 55
ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application
Hu, G., Tu, W., Liu, Y., Peng, G., & Yang, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.001 · Cited by 52
Abe, K., Kitago, M., Kitagawa, Y., & Hirasawa, A. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02015-6 · Cited by 62
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
Seeber, A., Zimmer, K., Kocher, F., Puccini, A., Xiu, J., Nabhan, C., Elliott, A., Goldberg, R. M., Grothey, A. F., Shields, A. F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000942 · Cited by 52
Self-citationUnderlying mechanisms and drug intervention strategies for the tumour microenvironment
Li, H., Zhou, L., Zhou, J., Li, Q., & Ji, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01893-y · Cited by 51
Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention
Whitaker, K. D., Obeid, E. I., Daly, M. B., & Hall, M. J. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00163 · Cited by 56
Self-citationBugazia, D., Al-Najjar, E., Esmail, A., Abdelrahim, S., Abboud, K., Abdelrahim, A., Umoru, G., Rayyan, H. A., Abudayyeh, A., Moustafa, A. A., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1386699 · Cited by 51
Molecular Subtyping and Precision Medicine for Pancreatic Cancer
Froeling, F. E. M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K.-F., & Precision-Panc, O. B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010149 · Cited by 52
Traub, B., Link, K. H., & Kornmann, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.030 · Cited by 51
Stossel, C., Raitses‐Gurevich, M., Atias, D., Beller, T., Gorman, Y. G., Halperin, S., Peer, E., Denroche, R. E., Zhang, A. X. W., Notta, F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0412 · Cited by 53
Self-citationDiscovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors
Fried, W., Tyagi, M., Станиславович, М. Л., Chandramouly, G., Tredinnick, T., Ramanjulu, M. M., Auerbacher, W., Calbert, M. L., Rusanov, T., Hoàng, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46593-1 · Cited by 53
Rebelatto, T. F., Falavigna, M., Pozzari, M., Spada, F., Cella, C. A., Laffi, A., Pellicori, S., & Fazio, N. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101895 · Cited by 50
Qi, S., Guan, X., Zhang, J., Yu, D., Yu, X., Li, Q., Yin, W., Cheng, X., Zhang, W., & Qin, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01538-4 · Cited by 50
Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
Taherian, M., Wang, H., & Wang, H. (2022) · Cells · doi:10.3390/cells11193068 · Cited by 52
Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma
Kaissis, G. A., Ziegelmayer, S., Lohöfer, F. K., Harder, F. N., Jungmann, F., Sasse, D., Muckenhuber, A., Yen, H.-Y., Steiger, K., Siveke, J. T., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030724 · Cited by 50
Nitecki, R., Melamed, A., Gockley, A. A., Floyd, J. L., Krause, K. J., Coleman, R. L., Matulonis, U. A., Giordano, S. H., Lu, K. H., & Rauh‐Hain, J. A. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.03.011 · Cited by 49
Güven, D. C., Şahin, T. K., Yildirim, H. Ç., Aktepe, O. H., Dızdar, Ö., & Yalçın, Ş. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103528 · Cited by 50
Pishvaian, M. J., Wang, H., He, A. R., Hwang, J. J., Smaglo, B. G., Kim, S. S., Weinberg, B. A., Weiner, L. M., Marshall, J. L., & Brody, J. R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1301 · Cited by 48
Metadata
- Authors
- Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E. M., McGuinness, D., Cui, K. Y., Schlienger, K., Locker, G. Y., & Kindler, H. L.
- Affiliations
- Tel Aviv University (IL)
- From the Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (T.G.); Hôpital Beaujon (Assistance Publique–Hôpitaux de Paris), Clichy, and University Paris VII, Paris (P.H.); IRCCS Ospedale San Raffaele Scientific Institute, Milan (M.R.), Azienda Ospedaliera Universitaria Integrata Verona, Verona (G.T.), and Fondazione Policlinico Universitario Gemelli IRCCS, Rome (G.T.) — all in Italy; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium (E.V.C.); Vall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 317-327
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6810605
- OpenAlex
- W2947826965
- Cited by
- 2,302
- References
- 24
- Citations by year
- 2026: 195 · 2025: 268 · 2024: 292 · 2023: 312 · 2022: 412 · 2021: 452 · 2020: 299 · 2019: 66
- FWCI
- 129.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- AstraZeneca (NA)
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc (NA)
- NIH/NCI Cancer Center Support Grant (P30-17 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, PARP inhibitors, germline BRCA mutation, metastatic pancreatic cancer, maintenance therapy, progression-free survival, overall survival, quality of life, adverse events, platinum-based chemotherapy, PARP inhibitor resistance, DNA repair deficiency, targeted therapy, interim analysis, predictive biomarkers, treatment discontinuation, health-related quality of life
- MeSH terms
- Progression-Free Survival, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pancreatic Neoplasms, Phthalazines, Piperazines, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
